AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8339493
Drug: Weight bearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight bearing during treatment
Trial: 23672055
Drug: Zaoren Anshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaoren Anshen capsules (five capsules)
Trial: 23672055
Drug: Zaoren Anshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaoren Anshen capsules
Trial: 8807172
Drug: 1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg‐1 lidocaine
Trial: 30141289
Drug: Ciloprost (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciloprost (100 mg, twice a day)
Trial: 24377889
Drug: Intracoronary adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary adenosine (2 mg)
Trial: 18983695
Drug: Intensive dose
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dose of renal replacement therapy
Trial: 18983695
Drug: Less-intensive dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive dose of renal replacement therapy
Trial: 14620915
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of IgG and IgM anti-MUC1 antibodies
Trial: 14620915
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of SM3 antibody
Trial: 27007018
Drug: Oral Impact
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Impact
Trial: 19858141
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (antihypertensive medication)
Trial: 16965225
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) monotherapy 500 mg twice daily in slow running infusion for twelve days followed by oral administration of 500 mg twice daily until delivery
Trial: 16965225
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) monotherapy 3x250 mg daily
Trial: 16965225
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of UDCA and SAMe
Trial: 11009047
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg b.i.d.) with mirtazapine (30 mg nocte)
Trial: 11009047
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with mirtazapine (30 mg nocte)
Trial: 8406286
Drug: Other lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other lipid-lowering agents
Trial: 8406286
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further medication
Trial: 2949396
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg b.i.d. for 14 days
Trial: 31712838
Drug: Palpation-guided corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided corticosteroid injection
Trial: 29883964
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg/h)
Trial: 21074212
Drug: Index tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Index tumor volume threshold of 0.5 ml
Trial: 17233236
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum in combination with counseling (motivational interviewing or health education)
Trial: 17233236
Drug: Placebo gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gum in combination with counseling (motivational interviewing or health education)
Trial: 9798802
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride (1.2 mg)
Trial: 9798802
Drug: Biperiden (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (5 mg)
Trial: 7636454
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan (6 mg per dose, one or two doses for a single migraine episode)
Trial: 7636454
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Acetaminophen
Trial: 2197532
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg pentamidine in 6 ml Aqua dest. with Inspiratory vital capacity breathing
Trial: 2197532
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg pentamidine in 6 ml Aqua dest.
Trial: 31081480
Drug: dual‐disorder treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dual‐disorder treatment of PTSD and SUD using prolonged exposure
Trial: 31081480
Drug: single‐disorder relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single‐disorder relapse prevention treatment for SUD
Trial: 27880052
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided BoNT‐A injections
Trial: 27880052
Drug: Electromyographic guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyographic guided BoNT‐A injections
Trial: 19345145
Drug: TK-cells infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TK-cells infusion
Trial: 11177331
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin once daily (1.5 mg/kg)
Trial: 11177331
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin twice daily (1.0 mg/kg)
Trial: 7889194
Drug: TCV-116 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-116 at 4 mg/day for 4 weeks
Trial: 4612057
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg morphine intravenously
Trial: 25106891
Drug: GnRHa therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa therapy (1.2 mg daily as nasal spray for 4 weeks before and 4 weeks after surgery)
Trial: 16100298
Drug: Darifenacin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 75 mg
Trial: 12047487
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release paracetamol (SR paracetamol), 4 g/day (two 665 mg tablets taken three times daily)
Trial: 12047487
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release paracetamol (IR paracetamol), 4 g/day (two 500 mg tablets taken four times daily)
Trial: 7032826
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg three times a day)
Trial: 7032826
Drug: Captopril (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (200 mg three times a day) + Placebo
Trial: 31679812
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group visits sessions (n=55)
Trial: 25450709
Drug: Besifovir 90
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir 90 mg
Trial: 25450709
Drug: Besifovir 150
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir 150 mg
Trial: 16732214
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia with propofol sedation and sub-Tenon's anaesthesia (lidocaine/mercaine infusion)
Trial: 10028206
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for 20 weeks
Trial: 2054266
Drug: Plain paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain paracetamol tablets 1000 mg every 6th hour
Trial: 2054266
Drug: Paracetamol slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol slow-release tablets 2000 mg every 12th hour
Trial: 6666216
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg orally administered ISDN
Trial: 31398634
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily routine exercises)
Trial: 15257922
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy combined with concomitant chemotherapy
Trial: 11571882
Drug: High-tech surgical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-tech surgical treatment modalities
Trial: 31597014
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg monophasic controlled-release oxycodone tablets
Trial: 31597014
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral solution oxycodone
Trial: 31597014
Drug: Controlled-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulations (both 20 mg tablets)
Trial: 29945259
Drug: Herbal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formulations (shampoo and solution)
Trial: 29945259
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of shampoo and solution
Trial: 26228675
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (0.5 g/d for 3 wk, then 1 g/d)
Trial: 21802126
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 2 months
Trial: 21802126
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 4 months
Trial: 17138173
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 4% articaine/HCl with 1:100,000 epinephrine injected into the buccal vestibule of the tooth
Trial: 14650862
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg once daily for 21 +/- 2 days)
Trial: 15508780
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (n = 32)
Trial: 6666224
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (80 mg once daily)
Trial: 6666224
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (80 mg twice daily)
Trial: 20077492
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (5-ALA) at a dosage of 5 mg/kg body weight administered prior to surgery
Trial: 17050563
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 25 mg alpha(1)-antitrypsin (AAT) daily for 4 weeks
Trial: 16262741
Drug: Artesunate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (4 mg/kg daily for 3 days) plus Amodiaquine (30 mg/kg over 3 days)
Trial: 16262741
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg/kg over 3 days) plus Pyrimethamine-Sulfadoxine (25 mg/kg of sulfadoxine at presentation)
Trial: 9802119
Drug: Combined cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive-behavioral and pharmacological therapy (fluoxetine for AN-R and AN-BP, amineptine for AN-BP and BN, fluvoxamine for BN)
Trial: 2506671
Drug: Heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treatment (subcutaneously administered clinical grade heparin)
Trial: 2506671
Drug: Nitrates and
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates and calcium-channel blockers without heparin
Trial: 742831
Drug: Combined analgesic-relaxant
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined analgesic-relaxant anaesthesia
Trial: 30203748
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride tablets
Trial: 30203748
Drug: Cervical vertebra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical vertebra exercises and cervical occipital belt traction therapy (reference group)
Trial: 26461996
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical therapy (4 sessions)
Trial: 24107292
Drug: Pitolisant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitolisant (10 mg, 20 mg, or 40 mg a day)
Trial: 24107292
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg, 200 mg, or 400 mg a day)
Trial: 21396086
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tablet containing 1 mg vitamin B12
Trial: 21396086
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: 11758131
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose nebulized albuterol (0.15 mg/kg)
Trial: 11758131
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose nebulized albuterol (0.075 mg/kg) plus ipratropium-bromide (250 micrograms/dose)
Trial: 9390958
Drug: CHO (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (0.75 g/kg) + Pro (0.1 g/kg) + Fat (0.02 g/kg)
Trial: 8426322
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of gentamicin and dexamethasone
Trial: 8426322
Drug: Collagen shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen shield without drug
Trial: 3624680
Drug: mPEG-modified honeybee
RxNorm normalized name: MPEG 6000 acetyl lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mPEG-modified honeybee venom (200 micrograms maintenance dose)
Trial: 3624680
Drug: unmodified honeybee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unmodified honeybee venom (100 micrograms maintenance dose)
Trial: 4573205
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment in epileptic patients
Trial: 4573205
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in epileptic patients
Trial: 4573205
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment in normal subjects
Trial: 4573205
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in normal subjects
Trial: 22835079
Drug: Parecoxib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (80 mg)
Trial: 21076089
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PEM and MR imaging
Trial: 12500005
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy in combination with Oral Rehydration Solution (ORS)
Trial: 12500005
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with Oral Rehydration Solution (ORS)
Trial: 8557897
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 24 hours
Trial: 8557897
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 72 hours
Trial: 8557897
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 0 hours (control group)
Trial: 1988573
Drug: Standard two‐cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard two‐cycle therapy
Trial: 1988573
Drug: Best induction/continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best induction/continuation therapy combination
Trial: 1988573
Drug: Four‐cycle continuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four‐cycle continuation therapy
Trial: 6409493
Drug: Kinetically based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetically based chemotherapy regimen before and after radiotherapy
Trial: 22476168
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation 4 g·d(‐1) for 1 week, then 6 g·d(‐1) for 4 weeks
Trial: 22104710
Drug: Intranasal citrate
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal citrate (0.3 M solution)
Trial: 22104710
Drug: Intranasal citrate
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal citrate with 2% lidocaine pretreatment
Trial: 22104710
Drug: Intranasal citrate
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal citrate mixed with 2% lidocaine
Trial: 10877199
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol 2 mg daily with sequential oral norethindrone acetate (NETA) 1 mg daily from days 12 to 22
Trial: 10877199
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol 0.05 mg daily with sequential oral NETA 1 mg daily from days 17 to 28
Trial: 30901496
Drug: Diploid genotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diploid genotypes under low-water availability treatment
Trial: 30901496
Drug: Hexaploid genotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexaploid genotypes under low-water availability treatment
Trial: 30901496
Drug: Both diploid
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both diploid and hexaploid genotypes under temperature and watering treatments
Trial: 30901496
Drug: Water availability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water availability treatment
Trial: 30901496
Drug: Temperature treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature treatment
Trial: 25255696
Drug: Immediate home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate home modifications (treatment group)
Trial: 23178035
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amyloid PET and MTA data
Trial: 21951559
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neuromuscular training program for 8 weeks and sports brace worn during all sports activities for 1 year
Trial: 16527696
Drug: BIRB 796
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIRB 796 (10, 20, 30, or 60 mg twice daily for 8 weeks)
Trial: 2871782
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day bevantolol
Trial: 2871782
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day bevantolol